Those reprogrammed cells are sent back and administered to the patient.The cells are taken to a manufacturing facility where they are reengineered to recognize cancer cells and wipe them out.In a healthy body, the immune system can recognize abnormal, cancerous cells, but for people with cancer it doesn't recognize that the cells are spreading. To start, a doctor removes some white blood cells, the part of our body's immune system responsible for combatting infections and foreign substances, from a patient.Since the therapy is made from a person's own immune system, the process can take about three weeks. These treatments aren't your run-of-the-mill pill - or even a biologic drug, like insulin - that can be mass-produced. Celgene said the treatment had the potential to hit $3 billion in global sales. Juno's furthest-along treatment, JCAR017, is expected to be approved in the US to treat another type of blood cancer called diffuse large B-cell lymphoma in 2019.
And in August, Gilead Sciences nabbed the CAR-T drugmaker Kite Pharma in a $12 billion deal. Celgene, which has been under pressure from investors to make some changes after a rocky 2017, has now made two acquisitions this month, after picking up Impact Biosciences in a $7 billion deal on January 7.Ģ017 was a big year for these CAR-T treatments: the Food and Drug Administration approved two treatments, one to treat acute lymphoblastic leukemia in people up to age 25 and another to treat aggressive B-cell non-Hodgkin lymphoma. "The acquisition of Juno builds on our shared vision to discover and develop transformative medicines for patients with incurable blood cancers," Celgene CEO Mark Alles said in a news release Monday. Juno is known for its experimental, highly personalized cancer treatments called CAR T-cell therapy (CAR is short for chimeric antigen receptor). Celgene, which already owned 9.7% of Juno's shares, will pay $87 a share in cash. The biotech giant is acquiring the cancer-drug maker in a $9 billion deal, Celgene said on Monday. The highly personalized treatments Juno makes, called CAR T-cell therapy, are at the beginning of an emerging field of medicine.It's the second deal in 2018 for the biotech giant, which has been under pressure from investors.
0 kommentar(er)
